Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.4952W HIGH $5.25
Volume
2.41 M
Value Traded
4.43 M
Short % Float
3.91%
Days to Cover
2.3
0%Week
+0.57%1 Month
+1.16%3 Month
+8.7%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
879.44 M
EPS (TTM)
0.01
P/E Ratio
525.00
Ent. Value
840.28 M
Total Shares
167.42 M
Float Shares
124.23 M
Insiders
0.41%
Institutions
74.51%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
TALK Catalyst Timeline
Dated clinical, regulatory and corporate events for Talkspace, Inc.
Past FDA Catalysts and PDUFA Decisions
How TALK actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Talkspace, Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every TALK program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Reilly John CharlesOfficer (Chief Legal Officer, Secretary) | Sell | -39,115 1,018,860 held | $5.20 | 06/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TALK
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in TALK for Q2 2026. | ||||
Ownership Trends
TALK Short Interest
Shares sold short, counted twice a month.
3.91%
Short % of Float
of tradable shares sold short
4.9M
Shares Sold Short
+18.2% vs prior count
2.3 Moderate
Days to Cover
trading days of normal volume to buy every short share back
2.1M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TALK ranks across every disease it competes in
Competitive Position is a premium feature
See how TALK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTALK News
About Talkspace, Inc.
Headquarters622 THIRD AVENUE, NEW YORK, NY, 10017
BIOPHARMAWATCH ELITE PLUS
Trade the next TALK catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime